Automated Cell Counter Market - By Product, By Application, By End Use - Global Forecast, 2026 - 2035

• The U.S. automated cell counter market was valued at USD 2.22 billion and USD 2.29 billion in 2022 and 2023, respectively. In 2025 the market size increased to USD 2.45 billion from USD 2.36 billion in 2024. This growth is primarily attributed to the increasing prevalence of chronic and infectious diseases.
   
• According to CDC, In the U.S. in 2022, 1,851,238 new cancer cases were reported, and in 2023, 613,349 people died of cancer. These figures highlight the growing need for accurate and timely diagnostics. Blood cell analysis, including complete blood counts (CBC), is a critical component in cancer detection and monitoring. Automated cell counters enable rapid, high-throughput testing, ensuring precision and efficiency in managing large patient volumes.
   
• The growing prevalence of conditions such as cancer, diabetes, and autoimmune diseases has significantly increased the need for precise cell counting technologies across U.S. Automated cell counters help hospitals and diagnostic labs deliver reliable results quickly, supporting early detection and personalized treatment plans. As healthcare providers prioritize efficiency and accuracy, the adoption of automated systems continues to accelerate, stimulating market growth.
   
• The U.S. leads in both usage and development of automated cell counter technologies due to its advanced healthcare infrastructure, high diagnostic testing volumes, and continuous investment in laboratory automation. Hospitals and diagnostic centers collaborate with leading manufacturers to integrate solutions such as AI-powered image-based counters and flow cytometry systems, ensuring better patient care and operational efficiency.
   

Europe Automated Cell Counter Market

Europe market accounted for USD 1.9 billion in 2025 and is anticipated to show lucrative growth over the forecast period.
 

• Europe is witnessing a steady increase in research and development expenditure, particularly in healthcare and life sciences. Governments and private organizations are allocating significant budgets to support innovation in diagnostics, drug discovery, and cell-based therapies. This increase in funding creates a strong foundation for adopting advanced laboratory technologies, including automated cell counters, which are essential for high-throughput and accurate cell analysis in research settings.
   
• For instance, According to EFPIA, the European pharmaceutical industry invested approximately €50 billion in healthcare-related research and development in 2023, marking a steady increase from €47 billion in 2022. . This spending supports innovation in drug discovery, diagnostics, and advanced therapies, including cell-based research.
   
• Higher research and development spending accelerates the development of new treatments and personalized medicine approaches, both of which require precise cell counting and characterization. Automated cell counters enable researchers to process large sample volumes efficiently, maintain reproducibility, and integrate data seamlessly into analytical workflows. As European countries focus on cutting-edge research in oncology, immunology, and regenerative medicine, the demand for automated cell counting solutions continues to rise, driving market growth.
   

Germany's automated cell counter market is projected to experience steady growth between 2026 and 2035.
 

• Germany’s market is experiencing steady growth due to the increasing research and development expenditure.
   
• Germany is one of Europe’s largest investors in pharmaceutical and healthcare research. According to EFPIA, the country allocated €8,540 million to pharmaceutical industry research and development in 2021, making it the top contributor in Europe.
   
• This significant investment reflects Germany’s commitment to advancing diagnostics, drug discovery, and cell-based therapies. Such funding creates a strong foundation for adopting advanced laboratory technologies, including automated cell counters, which are essential for high-throughput and accurate cell analysis in research and clinical settings.
   

Asia Pacific Automated Cell Counter Market

The Asia Pacific region is projected to show a lucrative growth of about 6.9% during the forecast period.
 

• The automated cell counter market in Asia Pacific is expanding steadily, driven by rising prevalence of chronic and infectious diseases.
   
• Automated cell counters offer speed, accuracy, and scalability, making them indispensable for managing large patient volumes and supporting public health initiatives.
   
• For instance, According to WHO, the South-East Asia (SEA) Region, which accounts for nearly one-fourth of the world’s population, bears more than 45% of the global annual TB incidence. In 2022 alone, over 4.8 million people fell ill with tuberculosis, and more than 600,000 died (excluding HIV+TB mortality), representing more than half of global TB deaths. Such alarming figures highlight the urgent need for advanced diagnostic solutions, including automated cell counters, which play a critical role in monitoring blood cells and immune responses in TB and other infectious diseases.
   
• The increasing burden of diseases like tuberculosis, HIV, and cancer drives demand for rapid, accurate, and high-throughput testing in hospitals, diagnostic laboratories, and research institutions across Asia-Pacific.
   

China automated cell counter market is poised to witness lucrative growth between 2026 - 2035.
 

• The market in China is expanding rapidly, driven by the increasing prevalence of chronic diseases such as cancer.
   
• Automated cell counters offer speed, accuracy, and scalability, making them indispensable for managing large patient volumes and supporting oncology diagnostics and research.
   
• For instance, according to global cancer observatory data, China reported 4,824,703 new cancer cases in 2022, with 2,574,176 deaths and 10,968,974 prevalent cases within five years of diagnosis. These figures highlight the urgent need for advanced diagnostic solutions, including automated cell counters, which play a critical role in blood cell analysis, immune profiling, and monitoring treatment response in cancer care.
   
• The increasing burden of diseases like cancer, diabetes, and other chronic conditions drives demand for rapid, accurate, and high throughput testing in hospitals, diagnostic laboratories, and research institutions across China.
   

Latin America Automated Cell Counter Market

Brazil is experiencing significant growth in the market.
 

• The growth of the market in the country is highly attributed to technological advancements and the introduction of innovative automated cell counter devices, along with the increasing prevalence of chronic and infectious disease in Brazil.
   
• Modern laboratories and healthcare facilities in Brazil are increasingly adopting automated systems that deliver faster, more accurate, and reproducible cell analysis compared to manual methods.
   
• As a result, technological advancements are accelerating the growth of Brazil’s automated cell counter market by improving speed, accuracy, and efficiency. With increasing adoption of AI-driven and cloud-enabled systems, Brazil is strengthening its diagnostic capabilities and supporting personalized medicine, ensuring continued market expansion.
   

Middle East and Africa Automated Cell Counter Market

• Saudi Arabia is steadily increasing its research and development expenditure, particularly in healthcare and life sciences. The government and private sector are investing heavily in modernizing healthcare infrastructure and supporting innovation in diagnostics, drug discovery, and cell-based therapies.
   
• These initiatives create a strong foundation for adopting advanced laboratory technologies, including automated cell counters, which are essential for high-throughput and accurate cell analysis in clinical and research settings.
   
• Higher research and development spending accelerates the development of personalized medicine, oncology research, and regenerative therapies all of which require precise cell counting and characterization.
   

Automated Cell Counter Market Share

• Leading companies in the automated cell counters market are actively strengthening their global footprint through strategic initiatives. These include acquisitions, partnerships, and technology-driven collaborations aimed at securing long-term growth in this rapidly evolving segment. Top 5 players Thermo Fisher Scientific, Danaher, Sysmex Corporation, Abbott Laboratories, and Revvity (Nexcelom Bioscience) collectively hold a market share of approximately 65% in the global automated cell counter market.
   
• Their product portfolios now feature next-generation cell counting technologies, including high-throughput systems, AI-powered image analysis, and integrated multi-parameter solutions. By incorporating advanced automation and connectivity features, these players are enabling real-time data monitoring, remote diagnostics, and streamlined workflows for laboratories and healthcare facilities.
   
• Close collaboration with clinical laboratories, research institutions, and regulatory authorities remains central to their strategy, ensuring compliance with stringent quality standards and data integrity norms. At the same time, efforts to expand access in emerging markets and support growing demand from biopharma and academic research sectors are making automated cell counting more widely available.
   
• Through continuous innovation, these companies are redefining cell analysis workflows, enhancing accuracy, reducing manual errors, and accelerating turnaround times. Their commitment to precision, scalability, and evidence-based practices is shaping modern laboratory protocols and supporting sustainable healthcare and research ecosystems worldwide.
   

Automated Cell Counter Market Companies

Few of the prominent players operating in the automated cell counter industry include:

• Thermo Fisher Scientific
• PerkinElmer
• Bio-Rad Laboratories
• Abbott Laboratories
• Sysmex Corporation
• NanoEnTek
• F. Hoffmann-La Roche Ltd
• Danaher
• Agilent Technologies
• Merck KGaA
• ChemoMetec A/S
• Logos Biosystems
• Nexcelom Bioscience (Revvity)
• DeNovix
• Curiosis
   
• Revvity (Nexcelom Bioscience)

Revvity, through Nexcelom Bioscience, specializes in fluorescence image-based cell counters designed for research and cell therapy applications. The company emphasizes innovation in multi-parameter analysis and high-throughput capabilities, enabling advanced workflows in biopharma and regenerative medicine. Its focus on precision and user-friendly design makes Revvity a preferred choice for cutting-edge cell analysis.
 

• Abbott Laboratories

Abbott Laboratories is a major contributor to automated cell counting through its hematology platforms based on the Coulter principle. The company focuses on delivering robust, high-throughput solutions for clinical laboratories, ensuring accuracy and reliability in routine diagnostics. Abbott’s strong presence in healthcare and commitment to operational excellence position it as a trusted provider in the automated cell counter market.
 

• Merck KGaA

Merck KGaA is a recognized player in the automated cell counting market, focusing on delivering innovative solutions that enhance accuracy and efficiency in cell analysis workflows. The company emphasizes portability and user-friendly designs, supporting research and biopharmaceutical applications where flexibility and reliability are critical. Through continuous investment in advanced technologies and global support infrastructure, Merck strengthens its position as a trusted partner for modern laboratory operations.
 

Automated Cell Counter Market News:

• In May 2021, PerkinElmer announced that it had entered into an agreement to acquire Nexcelom Bioscience in a cash transaction. Nexcelom was recognized as a global leader in automated cell counting instruments, image cytometry workstations, assays, and a wide range of cell reagents and consumables. The company also provided fit-for-purpose cell counting method development aligned with ISO standards, supporting advancements in cell and gene therapy, immuno-oncology, virology, and vaccine development. This acquisition strengthened PerkinElmer’s preclinical portfolio and enhanced its quality assurance and quality control capabilities in biologics manufacturing and cell-based research.